KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Liabilities and Shareholders Equity (2017 - 2025)

Amneal Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 9 years, most recently at $3.7 billion for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $3.7 billion for Q4 2025, up 5.05% from a year ago — trailing twelve months through Dec 2025 was $14.1 billion (up 0.99% YoY), and the annual figure for FY2025 was $3.7 billion, up 5.05%.
  • Liabilities and Shareholders Equity for Q4 2025 was $3.7 billion at Amneal Pharmaceuticals, up from $3.6 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for AMRX hit a ceiling of $4.0 billion in Q2 2022 and a floor of $3.4 billion in Q1 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $3.7 billion (2023), compared with a mean of $3.7 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: decreased 9.81% in 2021 and later increased 5.05% in 2025.
  • Amneal Pharmaceuticals' Liabilities and Shareholders Equity stood at $3.9 billion in 2021, then dropped by 3.56% to $3.8 billion in 2022, then fell by 8.6% to $3.5 billion in 2023, then grew by 0.83% to $3.5 billion in 2024, then rose by 5.05% to $3.7 billion in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $3.7 billion (Q4 2025), $3.6 billion (Q3 2025), and $3.4 billion (Q2 2025) per Business Quant data.